✦ LIBER ✦

Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma

✍ Scribed by Kensei Tobinai; Takashi Watanabe; Michinori Ogura; Yasuo Morishima; Tomomitsu Hotta; Kenichi Ishizawa; Kuniaki Itoh; Shin-ichiro Okamoto; Masafumi Taniwaki; Norifumi Tsukamoto; Hirokazu Okumura; Takashi Terauchi; Shigeru Nawano; Masaki Matsusako; Yoshihiro Matsuno; Shigeo Nakamura; Shigeo Mori; Yasuo Ohashi; Masaki Hayashi; Keigo Endo

Book ID: 108586335
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 142 KB
Volume: 100
Category: Article
ISSN: 1347-9032
DOI: 10.1111/j.1349-7006.2008.00999.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study of radioimmunotherapy with

Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (90Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma

✍ Takashi Watanabe; Shoji Terui; Kuniaki Itoh; Takashi Terauchi; Tadahiko Igarashi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

Phase I/II90Y-Zevalin (yttrium-90 ibritu

Phase I/II90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma

✍ Gregory A. Wiseman; Christine A. White; Michael Stabin; William L. Dunn; William 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 166 KB

Long-term responses in patients with rec

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

✍ Thomas E. Witzig; Arturo Molina; Leo I. Gordon; Christos Emmanouilides; Russell 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB

## Abstract ## BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non‐Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. ## METHODS. Data on patients with recurring NHL treated w

Biodistribution, radiation dosimetry and

Biodistribution, radiation dosimetry and scouting of90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using89Zr-ibritumomab tiuxetan and PET

✍ Saiyada N. F. Rizvi; Otto J. Visser; Maria J. W. D. Vosjan; Arthur van Lingen; O 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 284 KB

Multicenter phase II study of bendamusti

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

✍ Ken Ohmachi; Kiyoshi Ando; Michinori Ogura; Toshiki Uchida; Kuniaki Itoh; Nobuko 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB

High activity 90Y-ibritumomab tiuxetan (

High activity 90Y-ibritumomab tiuxetan (Zevalin®) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas

✍ Pier F. Ferrucci; Anna Vanazzi; Chiara M. Grana; Marta Cremonesi; Mirco Bartolom 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB